Until we have larger, more definitive studies, the safest approach is still to stop GLP-1 medications before trying to conceive. The findings, however, are exactly the kind of data we need to justify properly designed prospective trials, says Lora Shahine, MD, a reproductive endocrinologist and obstetrician-gynecologist at PNWF IVY Fertility Center in Bellevue, Washington, and host of the Brave and Curious podcast
"Mounjaro Product information"
However, BPC 157 is a therapeutic agent not approved by the FDA, which cites risk of immunogenicity, peptide-related impurities, and limited safety-related information as reasons for banning BPC-157
Understanding how tirzepatide regulates blood sugar through glucose-dependent mechanisms is essential for both healthcare providers and patients when assessing the medication's safety profile, particularly regarding hypoglycemia risk